Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lauric Haber

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|March 3, 2009
Improving antibody binding affinity and specificity for therapeutic developmentJenny Bostrom, Chingwei V Lee, Lauric Haber, et al.
Plos One|April 29, 2011
High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticityJenny Bostrom, Lauric Haber, Patrick Koenig, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 9, 2005
A general method for greatly improving the affinity of antibodies by using combinatorial librariesArvind Rajpal, Nurten Beyaz, Lauric Haber, et al.
Clinical and Translational Science|December 9, 2024
Translational findings support regimen selection for first-in-human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancerMin Zhu, Priyanka Madia, Alison Crawford, et al.
Clinical and Translational Science|January 8, 2022
Translational findings for odronextamab: From preclinical research to a first-in-human study in patients with CD20+ B-cell malignanciesMin Zhu, Kara Olson, Jessica R Kirshner, et al.
Cancer Immunology Research|March 19, 2020
A PSMA-Targeting CD3 Bispecific Antibody Induces Antitumor Responses that Are Enhanced by 4-1BB CostimulationDanica Chiu, Richard Tavaré, Lauric Haber, et al.
Cancer Cell|October 22, 2011
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodiesGabriele Schaefer, Lauric Haber, Lisa M Crocker, et al.
Science Translational Medicine|June 21, 2019
A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancerAlison Crawford, Lauric Haber, Marcus P Kelly, et al.
Scientific Reports|July 14, 2021
Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuningLauric Haber, Kara Olson, Marcus P Kelly, et al.
Science Translational Medicine|January 10, 2020
A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodiesDimitris Skokos, Janelle C Waite, Lauric Haber, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Methods in Molecular Biology (Clifton, N.J.)|March 3, 2009
Improving antibody binding affinity and specificity for therapeutic developmentJenny Bostrom, Chingwei V Lee, Lauric Haber, et al.
Plos One|April 29, 2011
High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticityJenny Bostrom, Lauric Haber, Patrick Koenig, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 9, 2005
A general method for greatly improving the affinity of antibodies by using combinatorial librariesArvind Rajpal, Nurten Beyaz, Lauric Haber, et al.
Clinical and Translational Science|December 9, 2024
Translational findings support regimen selection for first-in-human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancerMin Zhu, Priyanka Madia, Alison Crawford, et al.
Clinical and Translational Science|January 8, 2022
Translational findings for odronextamab: From preclinical research to a first-in-human study in patients with CD20+ B-cell malignanciesMin Zhu, Kara Olson, Jessica R Kirshner, et al.
Cancer Immunology Research|March 19, 2020
A PSMA-Targeting CD3 Bispecific Antibody Induces Antitumor Responses that Are Enhanced by 4-1BB CostimulationDanica Chiu, Richard Tavaré, Lauric Haber, et al.
Cancer Cell|October 22, 2011
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodiesGabriele Schaefer, Lauric Haber, Lisa M Crocker, et al.
Science Translational Medicine|June 21, 2019
A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancerAlison Crawford, Lauric Haber, Marcus P Kelly, et al.
Scientific Reports|July 14, 2021
Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuningLauric Haber, Kara Olson, Marcus P Kelly, et al.
Science Translational Medicine|January 10, 2020
A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodiesDimitris Skokos, Janelle C Waite, Lauric Haber, et al.
Pageof 2